SpaceStation MRI protects infusion pumps from magnetic fields, allowing for uninterrupted delivery of medication during imaging.
B. Braun Medical announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for SpaceStation MRI, a system that improves the use of infusion pumps in the MRI suite.
According to company information, SpaceStation MRI will enable the continuous delivery of medication to patients with Space® infusion pumps. It shields imaging pumps from 1.5T and 3T magnetic fields, both protecting the scanner and facilitating the capture of interference-free images.
“Clearance of the SpaceStation MRI represents a significant development for patients and healthcare providers,” said Angela Karpf, M.D., corporate vice president of medical affairs at B. Braun. “It will allow patients to be safely transitioned into the MRI suite without the interruption of infusion therapy since there is no need to switch to an alternative pump.”
With this system, she said, long infusion pump lines are not necessary, and hospital-wide Space® infusion pumps can safely transition patients into the imaging suite with the SpaceStation MRI. The system can accommodate adults, children, and newborns.
Based on a company statement, the SpaceStation MRI can continuously monitor the magnetic field strength to ensure proper placement and positioning, and it holds up to four space pumps, including the Infusomat® Space® Large Volume Pump, Perfursor® Space® Syringe Pump, and the Perfusor® PCA Syringe Pump.
In addition, company details said, a pump status window with a centralized alarm display allows technologists to continuously monitor infusions during imaging. The system also includes full drug library software with reference materials that can be used for dose reduction and online collaborations.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.